Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial
We present findings from the ANTHALYA study in women with advanced ovarian cancer. The complete resection rate at interval debulking surgery was examined. Bevacizumab-containing neoadjuvant therapy achieved 58.6% complete resection rate at interval debulking surgery. The incidence of perioperative complications with bevacizumab was acceptable. The role of bevacizumab in this setting should be further investigated.